Clinical overview of mesna
- PMID: 6414692
- DOI: 10.1016/s0305-7372(83)80026-7
Clinical overview of mesna
Abstract
Mesna is superior to standard prophylaxis in inhibiting the urotoxicity of oxazaphosphorines. Mesna does not interfere with the antitumour effect of oxazaphosphorines and other cytostatics. Mesna is well tolerated. Mesna can be given orally. Mesna should be administered with each ifosfamide treatment and with high dose cyclophosphamide. It should also be given to any patient who may be at risk of developing cystitis following oxazaphosphorine treatment.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
